Liquidia (LQDA) to Release Earnings on Wednesday

Liquidia (NASDAQ:LQDA) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 7th. Analysts expect Liquidia to post earnings of ($0.35) per share for the quarter.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. The company had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. On average, analysts expect Liquidia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Liquidia Trading Up 3.4 %

Shares of NASDAQ:LQDA opened at $11.93 on Thursday. The firm has a market capitalization of $911.57 million, a PE ratio of -7.65 and a beta of 0.32. The business’s 50 day moving average is $12.48 and its 200-day moving average is $13.38. Liquidia has a 1-year low of $5.71 and a 1-year high of $16.99.

Insider Activity

In related news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the sale, the chief financial officer now owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the sale, the chief executive officer now directly owns 818,932 shares of the company’s stock, valued at approximately $10,261,217.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the sale, the chief financial officer now owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The disclosure for this sale can be found here. Insiders have sold 21,437 shares of company stock worth $268,549 over the last 90 days. 31.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Liquidia in a research report on Thursday, July 18th. Oppenheimer assumed coverage on shares of Liquidia in a research note on Tuesday, June 25th. They set a “market perform” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Liquidia in a report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.60.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).